In the first head-to-head comparison of two devices intended to protect against stroke in patients undergoing transcatheter aortic valve replacement (TAVR), the investigational Emboliner device performed comparably to the Sentinel device, which is approved by the U.S. Food and Drug Administration. The research was presented at the American College of Cardiology’s Annual Scientific Session (ACC.26).
This article was originally published on MedicalXpress.com

